Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Tolerability of SSR149415 in Major Depressive Disorder
NCT00358631Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jul 2006
- Primary completion
- Dec 2007
- Modality
- Allosteric Modulators, Orthosteric Ligands, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nelivaptan in major depressive disorder (MDD) (4 arms), sponsored by Sanofi. Primary endpoint: Hamilton Depression Rating Scale at Day 56. Started Jul 2006; status: completed.
02
Drugs
nelivaptan
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00358631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00358631.